

Amendments to the Claims:

Claims 1 to 20 cancelled.

21.(new) A vaccine comprising an HPV 16 L1 VLP, an HPV 18 L1 VLP, aluminium hydroxide and 3D MPL.

22.(new) A vaccine according to claim 1 wherein the VLPs are formulated using pre-adsorbed purified bulks of antigen or 3D MPL on aluminium hydroxide.

23.(new) A vaccine according to claim 2 wherein the VLP 16 and VLP18 purified bulk are added to aluminium hydroxide to obtain a ratio of 2 µg VLP/10 µg aluminium hydroxide.

24.(new) The vaccine of claim 1 consisting of an HPV 16 L1 VLP, an HPV 18 L1 VLP, aluminium hydroxide and 3D MPL.

25.(new) An HPV 16 L1 VLP formulated with alum/3D-MPL using pre-adsorbed purified bulk of antigen or 3D MPL on aluminium hydroxide or aluminium phosphate.

26.(new) An HPV 18 L1 VLP formulated with alum/3D-MPL using pre-adsorbed purified bulk of antigen or 3D MPL on aluminium hydroxide or aluminium phosphate.